Delving into the Latest Updates on p52-p36- GAP Vaccine(SCRI) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Malaria

Originator Organization

Seattle Children's Research Institute

Active Organization-

Inactive Organization

Seattle Children's Research Institute

Drug Highest PhaseDiscontinuedPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults. The study will also assess preliminary efficacy of p52-/p36- GAP vaccine following primary experimental challenge with P. falciparum sporozoites. Lastly, the study will assess immunogenicity of p52-/p36- GAP in malaria-naïve healthy adults and preliminary efficacy of p52-/p36- GAP vaccine following primary experimental re-challenge with P. falciparum sporozoites.

Start Date01 Mar 2010

Sponsor / Collaborator

Seattle Children's Research Institute

100 Clinical Results associated with p52-p36- GAP Vaccine(SCRI)

Login to view more data

100 Translational Medicine associated with p52-p36- GAP Vaccine(SCRI)

Login to view more data

100 Patents (Medical) associated with p52-p36- GAP Vaccine(SCRI)

Login to view more data

100 Deals associated with p52-p36- GAP Vaccine(SCRI)

Login to view more data